Risedronate Sodium Tablet, Film Coated
Product Images NDC 59762-0406

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 59762-0406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Chemical Structure Of Risedronate Sodium Hemi-pentahydrate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Risedronate Sodium For Oral Administration Contains The Equivalent Of 5, 30, 35, 75, Or 150 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Risedronate Sodium Tablets 01)

Chemical structure of risedronate sodium, showing its molecular formula with sodium, phosphorus, oxygen, carbon, hydrogen, and nitrogen atoms, including 2.5 water molecules of hydration indicated.*

FDA Label Image

Figure 1 (Risedronate Sodium Tablets 02)

A bar graph titled 'Nonvertebral Osteoporosis-Related Fractures Cumulative Incidence Over 3 Years Combined VERT MN and VERT NA' showing the percentage of patients with fractures at different sites. The graph compares placebo and Risedronate Sodium 5 mg groups across fracture sites including All, Wrist, Humerus, Hip, Pelvis, Leg, and Clavicle.*

FDA Label Image

Figure 2 (Risedronate Sodium Tablets 03)

A bar graph titled 'Change in BMD from Baseline 2-Year Prevention Study' comparing mean percent change in bone mineral density (BMD) at three sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. It contrasts placebo (white bars) with Risedronate Sodium 5 mg (black bars), showing positive BMD changes for Risedronate Sodium at all sites versus negative or lower changes for placebo.*

FDA Label Image

Figure 3 (Risedronate Sodium Tablets 04)

A bar chart depicting the change in bone mineral density (BMD) from baseline in patients recently initiating glucocorticoid therapy. The chart compares BMD percentage changes for lumbar spine, femoral neck, and femoral trochanter regions between placebo and Risedronate Sodium 5 mg groups, with sample sizes indicated for each group.*

FDA Label Image

Figure 4 (Risedronate Sodium Tablets 05)

A bar graph titled 'Change in BMD from Baseline Patients on Long-Term Glucocorticoid Therapy' comparing percent change in bone mineral density (BMD) between placebo and Risedronate Sodium 5 mg groups at three sites: lumbar spine, femoral neck, and femoral trochanter. The graph shows mean percent change with standard error for each group, with sample sizes noted above each bar.*

FDA Label Image

Figure 5 (Risedronate Sodium Tablets 06)

A bar graph titled 'Incidence of Vertebral Fractures in Patients Initiating or Continuing Glucocorticoid Therapy' comparing the incidence percentages between placebo and Risedronate Sodium 5 mg groups. It shows three categories: patients continuing glucocorticoid treatment, patients initiating glucocorticoid treatment, and combined groups, with incidence percentages on the vertical axis and sample sizes noted above each bar.*

FDA Label Image

Figure 6 (Risedronate Sodium Tablets 07)

A line graph showing the mean percent change from baseline in serum alkaline phosphatase excess over time (Visit Days) comparing DIDRONEL 400 mg and Risedronate Sodium 30 mg. The graph includes markers for sample sizes at various time points during treatment, follow-up, and extended follow-up phases, with Risedronate Sodium showing a steeper and sustained decrease.*

FDA Label Image

Greenstone (Risedronate Sodium Tablets 08)

FDA Label Image

Ndc 59762-0405-4risedronate Sodium Tablets35 mgonce-a-week4 Tabletsrx Only (Risedronate Sodium Tablets 0a)

Packaging label for Greenstone Brand risedronate sodium tablets, 35 mg. The label specifies a 4-week supply (4 tablets) for once-a-week dosing. It includes the NDC 59762-0405-4 and indicates prescription use only. The labeler is Greenstone LLC.*

FDA Label Image

Ndc 59762-0405-4risedronate Sodium Tablets35 mgonce-a-week4 Tabletsrx Only (Risedronate Sodium Tablets 0b)

Packaging label for Greenstone brand Risedronate Sodium tablets, 35 mg strength. The box contains a 4 week supply of 4 film-coated tablets, intended for oral use. The label includes child-resistant package opening instructions and medication guide information. The product is labeled as prescription only and manufactured by Mylan Pharmaceuticals, Inc.*

FDA Label Image

Ndc 59762-0405-5risedronate Sodium Tablets35 mg12 Week Supply12 (risedronate sodium tabletsRx only)

Greenstone brand Risedronate Sodium 35 mg film-coated tablets packaging label. The label shows the proprietary and generic name, strength (35 mg), 12-week supply, prescription-only designation, NDC 59762-0405-5, and labeler Mylan Pharmaceuticals, Inc. The package is primarily white with teal and black text.*

FDA Label Image

Ndc 59762-0405-5risedronate Sodium Tablets35 mg12 Week Supply12 (risedronate sodium tabletsRx only)

Flat layout of a child-resistant packaging label for Risedronate Sodium tablets, 35 mg strength, by Mylan Pharmaceuticals, Inc. The label includes instructions on how to open the child-resistant package, dosage form as film-coated tablets, and indicates a 12-week supply with 12 tablets. The label features the Greenstone brand name and dosage information prominently on the front panel.*

FDA Label Image

Ndc 59762-0406-1risedronate Sodium Tablets150 mgone Month Pack(1 Tablet)rx Only (Risedronate Sodium Tablets 0e)

Packaging label for Risedronate Sodium 150 mg tablets by Greenstone Brand. The label indicates a prescription medication in tablet form, provided as a one-month pack containing one tablet. The label includes dosage strength, NDC 59762-0406-1, and instructions to dispense the Medication Guide to each patient.*

FDA Label Image

Ndc 59762-0406-1risedronate Sodium Tablets150 mgone Month Pack(1 Tablet)rx Only (Risedronate Sodium Tablets 0f)

Packaging label for 150 mg Risedronate Sodium tablets by Mylan Pharmaceuticals, Inc. The label indicates a one month supply with one tablet. Instructions for opening the child-resistant package and usage directions are included. The label features the Greenstone brand, barcode, and NDC number 59762-0406-1.*

FDA Label Image

Ndc 59762-0406-3risedronate Sodium Tablets150 mg3 Month Packrx Only (Risedronate Sodium Tablets 10)

Packaging label for Risedronate Sodium tablets 150 mg by Mylan Pharmaceuticals, Inc. The label indicates a 3 month pack with monthly dosing instructions. The product is identified as prescription only and includes branding as Greenstone Brand.*

FDA Label Image

Ndc 59762-0406-3risedronate Sodium Tablets150 mg3 Month Packrx Only (Risedronate Sodium Tablets 11)

Packaging label for Risedronate Sodium tablets 150 mg, film-coated, oral dosage form by Mylan Pharmaceuticals, Inc. The carton includes instructions for opening a child-resistant package, indicates a 3-month supply pack with three tablets, and shows branding, dosage strength, and Rx only designation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.